Showing results (251-260 of 389) with videos related to
Sort By:
Pageof 39
Neuroendocrinology|November 5, 2015
Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?Roxanne C S van Adrichem, Kimberly Kamp, Carolien H M van Deurzen, et al.World Journal of Surgery|May 23, 1998
2-Methoxyisobutylisonitrile probe during parathyroid surgery: tool or gadget?H J Bonjer, H A Bruining, H A Pols, et al.European Journal of Endocrinology|June 29, 2002
The value of plasma markers for the clinical behaviour of phaeochromocytomasE van der Harst, W W de Herder, R R de Krijger, et al.European Journal of Nuclear Medicine and Molecular Imaging|July 24, 2013
Hypocalcaemia after treatment with [177Lu-DOTA 0,Tyr3]octreotateEsther I van Vliet, Wouter W de Herder, Yolanda B de Rijke, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 5, 2017
Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine TumorsHendrik Bergsma, Kirsten van Lom, Marc H G P Raaijmakers, et al.The Journal of Clinical Endocrinology and Metabolism|September 15, 2005
Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levelsR A Feelders, M Bidlingmaier, C J Strasburger, et al.Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 8, 2000
The role of radioactive somatostatin and its analogues in the control of tumor growthE P Krenning, R Valkema, P P Kooij, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 10, 1999
Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapyE P Krenning, M de Jong, P P Kooij, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumorsDik J Kwekkeboom, Jaap J Teunissen, Willem H Bakker, et al.The Journal of Clinical Endocrinology and Metabolism|May 6, 2004
Dopamine receptor expression and function in corticotroph pituitary tumorsRosario Pivonello, Diego Ferone, Wouter W de Herder, et al.Pageof 39